Phase II study of neoadjuvant durvalumab and tremelimumab in combination with gemcitabine and cisplatin in patients with intrahepatic cholangiocarcinoma that is borderline resectable or resectable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results